Drug Trial Radar · NCT04215809
Study of APG-2575 as a Single Agent or in Combination With Other Therapeutic Agents for CLL/SLL
Last checked: Nov 19, 2026Latest source record: Apr 10, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
144
Planned (sponsor's estimate)
Start
Mar 2, 2020
Primary completion
Oct 31, 2025
Study completion Jun 30, 2027
Sponsor
- Lead sponsor
- Ascentage Pharma Group Inc.Industry
- Sponsor type
- Industry
- First posted
- Jan 2, 2020
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 85 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Assess the safety and tolerability, identify dose-limiting toxicities (DLT) and determine the maximum tolerated dose (MTD) / recommended phase 2 dose (RP2D) of lisaftoclax.
Conditions
- CLL/SLL
Interventions
LisaftoclaxDrug
Lisaftoclax investigation drug in ramp up dosing
Primary outcomes
What the sponsor says the trial is designed to measure.
- Primary Toxicity Endpoint: dose limiting toxicity (DLT)Time frame: 42 days
- Maximally tolerated dose (MTD)Time frame: 42 days
Locations
9 sites in 2 countries. Site status is shown where the registry gives one.
City of Hope
Duarte, California · Recruiting
Mayo Clinic
Jacksonville, Florida · Recruiting
Dana Farber Cancer Institute
Boston, Massachusetts · Recruiting
Novant Health
Charlotte, North Carolina · Recruiting
Gabrail Cancer Center
Canton, Ohio · Recruiting
Cleveland Clinic
Cleveland, Ohio · Recruiting
Swedish Health
Seattle, Washington · Recruiting
Princess Alexandria Hospital
Brisbane, Queensland, Australia · Recruiting
Frankston Private Hospital
Melbourne, Victoria, Australia · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.